Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail shows promise for Hard-to-Treat cancers

NCT ID NCT03875820

First seen Mar 20, 2026 · Last updated Apr 30, 2026 · Updated 4 times

Summary

This early-phase trial tests a combination of two experimental drugs, defactinib and VS-6766, in people with advanced solid tumors that have not responded to standard treatments. The study includes patients with certain lung, ovarian, pancreatic, and endometrial cancers. The main goal is to find the safest dose and understand side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • The Christie NHS Foundation Trust

    Manchester, Greater Manchester, M20 4BX, United Kingdom

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital

    Newcastle, NE7 7DN, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, SM2 5PT, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Gynecology Unit

    London, SW3 6JJ, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Gynecology Unit

    Sutton, SM2 5PT, United Kingdom

Conditions

Explore the condition pages connected to this study.